Jiaying Lian
Overview
Explore the profile of Jiaying Lian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lian J, Jiang Y, Lou M, Kong L
Arch Dermatol Res
. 2025 Jan;
317(1):271.
PMID: 39821646
No abstract available.
2.
Lian J, Zhuang H, Li F, Pei R, Chen D, Ye P, et al.
Hematology
. 2024 Aug;
29(1):2381171.
PMID: 39087796
Background: Acute myeloid leukemia (AML) is a heterogeneous disease, for which identifying reliable prognostic markers is critical for accurate clinical prognosis and treatment optimization. The inhibition of emopamil-binding protein gene...
3.
Li K, Wang Y, Pei R, Lu Y, Cao J, Zhuang X, et al.
Turk J Haematol
. 2024 Jul;
41(3):202-204.
PMID: 39078014
No abstract available.
4.
Lian J, Zhang B, Li K, Lu Y
Asian J Surg
. 2024 May;
47(9):4013-4015.
PMID: 38724357
No abstract available.
5.
Ye P, Cheng Y, Lian J, Tong H, Li L, Guo Q, et al.
Br J Haematol
. 2024 Feb;
204(6):2342-2350.
PMID: 38400570
A chemotherapy-based mobilization regimen in patients who mobilize poorly, based on etoposide, cytarabine and pegfilgrastim (EAP), has recently been introduced. The aim of this prospective study was to investigate the...
6.
Ye P, Pei R, Lian J, Chen D, Li S, Cheng Y, et al.
Cytotherapy
. 2023 May;
25(8):885-890.
PMID: 37212754
Background Aims: An optimal strategy for mobilizing hematopoietic stem cells in poorly mobilizing patients with multiple myeloma (MM) and lymphoma has not yet been determined. Methods: We retrospectively analyzed the...
7.
Zhuang H, Li F, Xu Y, Pei R, Chen D, Liu X, et al.
Ann Hematol
. 2023 Mar;
102(5):1063-1072.
PMID: 36959484
The transcription factor interferon regulatory factor 8 (IRF8), as a member of the IRF family, is essential for myeloid cell differentiation. However, the precise role of IRF8 in the pathogenesis...
8.
Li F, Ling Q, Lian J, Chen Y, Hu C, Yang M, et al.
Cancer Med
. 2023 Jan;
12(7):8319-8330.
PMID: 36621846
Background: Identifying therapeutic targets and prognostic biomarkers significantly contributes to individualized treatment of acute myeloid leukemia (AML). Dihydropyrimidinase-like 2 (DPYSL2) expression was decreased in homoharringtonine (HHT)-resistant AML cells, which were...